Fady I. Malik, M.D., Ph.D., serves as the Executive Vice President of Research and Development at Cytokinetics, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases. Dr. Malik has been with Cytokinetics since 2003, bringing over two decades of experience in drug discovery and development to his role. He holds dual degrees in medicine and pharmacology, having earned his M.D. and Ph.D. from the University of California, San Diego. In his tenure at Cytokinetics, Dr. Malik has been instrumental in advancing the company’s pipeline, particularly in the area of cardiovascular and neuromuscular diseases. He has led the development of several key drug candidates, including omecamtiv mecarbil, a novel cardiac muscle activator aimed at treating heart failure. His leadership has been pivotal in navigating these compounds through various stages of clinical trials, contributing significantly to the company's scientific advancements and its reputation in the biopharmaceutical industry. Dr. Malik's work has been recognized in numerous scientific publications, underscoring his role as a thought leader in the field of muscle biology and pharmacology. As Executive Vice President of Research and Development, Dr. Malik oversees a broad spectrum of activities, from early-stage research to late-stage clinical development. His strategic vision and deep understanding of both the scientific and clinical aspects of drug development have been crucial in steering Cytokinetics towards its goal of bringing innovative therapies to patients in need. Beyond his corporate responsibilities, Dr. Malik remains actively engaged in the scientific community, often presenting at conferences and contributing to collaborative research efforts aimed at advancing the understanding and treatment of muscle-related diseases.